A
Aclaris Therapeutics D
D
ACRS
5.27500
USD
-0.17
(-3.03%)
مغلق
حجم التداول
109,675
الربح لكل سهم
-1
العائد الربحي
-
P/E
-9
حجم السوق
776,474,161
المقالات
العنوان: Aclaris Therapeutics
القطاع: الرعاية الصحية
الصناعة: Biotechnology
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.